Update on MS treatment.
Ryan
M
M
Department of Neurology, College of Medicine, University of Kentucky, Lexington, USA.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007275:Injections, Intravenous; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000503:physiopathology / Q000628:therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a